Maxigen Biotech Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was TWD 170.92 million compared to TWD 154.23 million a year ago. Net income was TWD 62.35 million compared to TWD 33.49 million a year ago. Basic earnings per share from continuing operations was TWD 0.7048 compared to TWD 0.381 a year ago. Diluted earnings per share from continuing operations was TWD 0.7048 compared to TWD 0.3714 a year ago.
For the six months, sales was TWD 313.95 million compared to TWD 277.49 million a year ago. Net income was TWD 106.8 million compared to TWD 54.03 million a year ago. Basic earnings per share from continuing operations was TWD 1.2 compared to TWD 0.6095 a year ago. Diluted earnings per share from continuing operations was TWD 1.2 compared to TWD 0.6095 a year ago.